A previously overlooked enzyme called APOBEC3A is linked to the most prevalent mutational signatures in cancer cell lines, a study finds.

Tumors contain thousands of genetic changes, but only a few are actually cancer-causing. A quicker way to identify these driver mutations could lead to more targeted cancer treatments.

Analyzing the whole genome sequences of more than 18,000 tumors, researchers catalog nearly 60 new patterns of mutations that could inform cancer treatment.

This year revealed just how much scientists have learned about the disease, from how animals become naturally cancer-resistant to how tumor cells harness extracellular DNA to develop rapid drug resistance.

The Scientist spoke with University of Liverpool aging and longevity researcher João Pedro de Magalhães about how human biases can influence scientific priorities and outcomes in genetics.

In the last decade, researchers have come to realize that tumors harbor bits of extrachromosomal DNA that can drive malignancy.

An interrogation of the whole genomes of more than 2,600 cancers yields clues about the genetic drivers of malignancy, how tumors evolve, and more.

Its screen for selected variants of some disease-linked genes gives customers an incomplete picture of their risk—do they know?

Fly avatars bearing multiple genetic changes akin to those of a cancer patient lead to a tailor-made treatment that has shrunk the patient’s tumors.

Computational biologist Jinghui Zhang of St. Jude realized scientists could work more efficiently with tools and genomic data shared on the cloud.

In the largest study of its kind to date, researchers find more than 850 rare, heritable genetic alterations that can predispose humans to cancer.

Two large-scale studies reveal new insights into the genomic characteristics of childhood cancers.

China shows the biggest increase of any country in the number of scientists listed since last year, while cancer genomics emerges as one of the more dominant fields.

The publicly available database found nearly a third of samples included mutations targeted by either approved drugs or therapies in clinical trials. 

At the University of California, Santa Cruz, the researcher combs the cancer genome, looking for weaknesses.

April Scientist to Watch Angela Brooks of the University of California, Santa Cruz, discusses her search to find vulnerabilities buried within the genomes of cancer cells.

The genomics pioneer shares the sessions she most looks forward to at this year’s American Association for Cancer Research annual meeting.